U.S. Markets closed

Aethlon Medical, Inc. (AEMD)


NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
2.13-0.20 (-8.58%)
At close: 4:00PM EDT
People also watch
CTSOADMPAMARAKERBLFS
Full screen
Previous Close2.33
Open2.29
Bid2.05 x 300
Ask3.10 x 100
Day's Range2.13 - 2.37
52 Week Range1.53 - 9.09
Volume35,828
Avg. Volume53,829
Market Cap18.74M
Beta2.75
PE Ratio (TTM)-2.41
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Zacks Small Cap Research2 months ago

    AEMD: Feasibility Study Complete. FDA Discussions Expected To Follow

    Operational Update:  Feasibility Study Done, Safety Appears Non-Issue. In mid-March AEMD announced the completion of their U.S. feasibility study.  While expected to enroll 10 subjects, final enrollment was 8 patients with ESRD or HCV – which the company deemed sufficient given no evidence of treatment-related adverse events (i.e.

  • Zacks Small Cap Research4 months ago

    AEMD: FDA Discussions Regarding U.S. Clearance Pathway

    Aethlon (AEMD) reported financial results for their fiscal third quarter 2017 (ending December 2016) and provided an operational update.  There were no meaningful surprises in the financial results relative to our expectations with the top-line ($0 A vs. $8k E), operating expenses ($1.2M A vs. $1.3M E), net loss ($1.2M A vs. $1.3M E) and EPS (-$0.15 A vs. -$0.16) E) all coming in just about exactly where we had modeled. Relative to the balance sheet, AEMD exited fiscal Q3 with $628k cash and equivalents.  They raised $288k and $578k (net) from the sale of equity (via ATM) and convertible notes, respectively, during the quarter.  Subsequent to quarter-end, AEMD raised an additional $256k (net) via the sale of 64k common shares @ $3.98/share average through their ATM program.  Aethlon raised ~$810k through the ATM program since the beginning of Q2 and there remains ~$11M still available.

  • Zacks Small Cap Research5 months ago

    AEMD: New CTE Study Largest in Ex-NFL Players

    Following conclusion of the DARPA DLT sepsis-related program, Aethlon (AEMD) wasted little time in allocating its focus on other high-priority programs, including further validation of Hemopurifier in the capture of certain viruses and pathogens  - progress which could lead towards eventually utility of the device in a variety applications including as a broad spectrum countermeasure against viral pathogens – an objective which also aligned with the Public Health Emergency Medical Countermeasures Enterprise’s (PHEMCE) goal of developing broad-spectrum medical countermeasures (MCM).  The company also continues to move forward on other applications of Hemopurifier, including potentially in sepsis.